Alpha Biopharma (Jiangsu) Co., Ltd.
4 clinical trials · Sponsor
◉ Watch Alpha Biopharma (Jiangsu) Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China (NCT07620951) | Alpha Biopharma (Jiangsu) Co., Ltd. | 2026-07-06 |
| Zorifertinib With Osimertinib for NSCLC With Meningeal Progression (NCT07361705) | Alpha Biopharma (Jiangsu) Co., Ltd. | 2026-01-31 |
| A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases (NCT07143045) | Alpha Biopharma (Jiangsu) Co., Ltd. | 2025-12-29 |
| First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (NCT03653546) | Alpha Biopharma (Jiangsu) Co., Ltd. | 2018-10-29 |
Track Alpha Biopharma (Jiangsu) Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.